Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
- 23 September 2004
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 15 (2) , 143-151
- https://doi.org/10.1016/j.euroneuro.2004.07.001
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Polymorphism of the Promoter Region of the Serotonin 5-HT2C Receptor Gene and Clozapine-Induced Weight GainAmerican Journal of Psychiatry, 2003
- Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2 Receptor GeneAmerican Journal of Psychiatry, 2001
- Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patientsEuropean Neuropsychopharmacology, 1999
- Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia PatientsNeuropsychopharmacology, 1998
- D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allelePharmacogenetics, 1997
- Regulation of serotonin-2C receptor G-protein coupling by RNA editingNature, 1997
- Proposed Schizophrenia-Related Gene Polymorphism: Expression of the Ser9Gly Mutant Human Dopamine D3Receptor with the Semliki Forest Virus SystemBiochemical and Biophysical Research Communications, 1996
- Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antiseraNeuropharmacology, 1995
- Association between clozapine response and allelic variation in the 5-HT2C receptor geneNeuroReport, 1995
- Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disordersPsychiatric Genetics, 1992